Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation

Eur Urol. 2015 Aug;68(2):341-3. doi: 10.1016/j.eururo.2015.03.002. Epub 2015 Mar 18.

Authors

Siraj M Ali¹, Philip J Stephens¹, Vincent A Miller¹, Jeffrey S Ross², Sumanta Kumar Pal³

Affiliations

¹ Foundation Medicine, Cambridge, MA, USA.
² Foundation Medicine, Cambridge, MA, USA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY, USA.
³ Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: spal@coh.org.

PMID: 25796537
DOI: 10.1016/j.eururo.2015.03.002

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / genetics
Carcinoma, Renal Cell / secondary
DNA Mutational Analysis
Drug Substitution
Female
Genetic Predisposition to Disease
Humans
Kidney Neoplasms / drug therapy*
Kidney Neoplasms / enzymology
Kidney Neoplasms / genetics
Kidney Neoplasms / pathology
Mutation*
Phenotype
Protein Kinase Inhibitors / therapeutic use*
Sirolimus / analogs & derivatives*
Sirolimus / therapeutic use
TOR Serine-Threonine Kinases / antagonists & inhibitors*
TOR Serine-Threonine Kinases / metabolism
Time Factors
Tomography, X-Ray Computed
Treatment Outcome
Tuberous Sclerosis Complex 1 Protein
Tumor Suppressor Proteins / genetics*

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
TSC1 protein, human
Tuberous Sclerosis Complex 1 Protein
Tumor Suppressor Proteins
temsirolimus
MTOR protein, human
TOR Serine-Threonine Kinases
Sirolimus